Community involvement is embedded in Novo Nordisk's history and values. It involves a respectful weighing of business interest against those of stakeholders and society, a balancing of short-term and long-term interest. Novo Nordisk's overall approach to community engagement is primarily focused on the company's main area of expertise, namely diabetes. Whether it is about supporting long-term sustainable health with their communities, Novo Nordisk is at the forefront of providing treatment and care for people with diabetes.

Novo Nordisk has been involved in changing diabetes care in Canada since 1984. Today, with more than 300 employees working across the country, our vision is to defeat diabetes by finding better methods of diabetes prevention, detection and treatment. The need has never been more clear.

More than 11 million Canadians are living with diabetes or prediabetes. Every hour of every day, 20 people are diagnosed with diabetes. The burden of the disease, both to the individual and the healthcare system, is growing. By 2020, 10% of Canadians will be living with diabetes, and the burden of the disease will cost the healthcare system close to $17 billion annually.

Through our Changing Diabetes® ambition, Novo Nordisk is making a difference in the lives of people living with diabetes in Canada. Through partnerships with healthcare providers and not-for-profit organizations, we help drive research, advocacy and awareness initiatives to improve access to diabetes education, care and treatment for all Canadians impacted by the disease.

Grants and donations

Novo Nordisk Canada Inc. is socially responsible. We partner with and give contributions or financial support to organizations in support of healthcare, medical education, research, or other social impact initiatives that benefit patients, people and communities or the environment in line with our Triple Bottom Line business principle, thereby supporting Novo Nordisk’s long-term interests. We are committed to supporting causes in the therapeutic areas in which we operate - diabetes, obesity and rare diseases such as hemophilia and growth hormone disorder, as well as emerging therapeutic areas. If your organization has a request for a grant or donation that falls within one of these areas, we invite you to submit an application through our online system.

Novo Nordisk Canada is proud to have funded the following organizations:

  • Axe de recherche diabète, obésité et complications cardiovasculaires (DOCC) at the University of Sherbrooke
  • Axe Obésité, diabète de type 2 et métabolisme at Laval University
  • Banting & Best Diabetes Centre - University of Toronto
  • Camp Banting
  • Camp Carowanis
  • Camp d'ete pour jeunes diabetiques de l'est du Quebec Inc.
  • Canadian Cardiovascular Society
  • Canadian Hemophilia Society and provincial chapters
  • Canadian Liver Foundation
  • Community Foundation of Mississauga
  • Diabète Québec
  • Diabetes Canada
  • Diabetes Hope Foundation
  • Fondation de l'Hôpital Maisonneuve Rosemont
  • Fondation du Centre Hospitalier de L'université de Montréal
  • I Challenge Diabetes
  • Juvenile Diabetes Research Foundation (JDRF)
  • McGill University Health Centre
  • McMaster University
  • Montreal Diabetes Research Center
  • Obesity Canada
  • Ontario Physical and Health Education Association (OPHEA)
  • Réseau de recherche en Santé cardiométabolique, diabète et obésité (CMDO)
  • Royal Victoria Hospital Foundation
  • Schulich School of Medicine and Dentistry at Western University
  • Sunnybrook Health Sciences Centre Foundation
  • The Association of Hemophilia Clinic Directors of Canada
  • The Mississauga Food Bank
  • University of British Columbia
  • University of Ottawa Heart Institute

Click here to access the application for Grants and Donations.